Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
-- Alopecia areata is the second autoimmune indication being evaluated for bempikibart -- ...
Source: marketscreener.com